Speakers
Speakers
Dr. med. Andrea Jungaberle
Chief Medical Officer (OVID Clinic Berlin); Co-founder and Advisory Board Member (MIND Foundation)
A clinical specialist in anaesthesia and emergency medicine and a licensed psychotherapist, she has participated in multiple clinical trials involving psychedelics and holds, in collaboration with Prof. Gerd Gründer (ZI Mannheim), the license for compassionate use with psilocybin in Germany. Her work focuses on the therapeutic application of altered states of consciousness, integration, and end-of-life care.
Dr. med. Andrea Jungaberle
Chief Medical Officer (OVID Clinic Berlin); Co-founder and Advisory Board Member (MIND Foundation)
A clinical specialist in anaesthesia and emergency medicine and a licensed psychotherapist, she has participated in multiple clinical trials involving psychedelics and holds, in collaboration with Prof. Gerd Gründer (ZI Mannheim), the license for compassionate use with psilocybin in Germany. Her work focuses on the therapeutic application of altered states of consciousness, integration, and end-of-life care.
Dr Anne Kleinberg, MD
Child and Adolescent Psychiatrist; Psychotherapist (Kleinberg); Vice Chairman of the Board (Estonian Psychiatric Society)
She has worked as a child and adolescent psychiatrist since 2001. For nearly as long, she has been actively involved in the development of psychiatry as a medical specialty and in shaping mental health policy in Estonia. She also serves as Vice Chairman of the Board of the Estonian Psychiatric Society.
Dr Anne Kleinberg, MD
Child and Adolescent Psychiatrist; Psychotherapist (Kleinberg); Vice Chairman of the Board (Estonian Psychiatric Society)
She has worked as a child and adolescent psychiatrist since 2001. For nearly as long, she has been actively involved in the development of psychiatry as a medical specialty and in shaping mental health policy in Estonia. She also serves as Vice Chairman of the Board of the Estonian Psychiatric Society.
Dr David Erritzoe, MD, PhD, MRCPsych
Clinical Associate Professor of Psychopharmacology and Psychiatry; Director of the Centre for Psychedelic Research & CIPPRes Clinic (Imperial College London)
He is a psychiatrist and neuroscientist at Imperial College London, where he heads the Centre for Psychedelic Research and directs the NHS-based CIPPRes Clinic – one of the first clinical services of its kind to integrate psychedelic-assisted approaches into mainstream psychiatric care. His research combines PET, MRI and EEG brain imaging to investigate the neuromechanisms and therapeutic effects of psilocybin, MDMA, DMT and ketamine across conditions including depression, OCD, anorexia nervosa and addiction. Ranked in the top 0.1% of scientists globally in 2025 and the recipient of Imperial's President Award for Excellence in Research, he brings both scientific rigour and clinical depth to one of psychiatry's most rapidly advancing frontiers.
Dr David Erritzoe, MD, PhD, MRCPsych
Clinical Associate Professor of Psychopharmacology and Psychiatry; Director of the Centre for Psychedelic Research & CIPPRes Clinic (Imperial College London)
He is a psychiatrist and neuroscientist at Imperial College London, where he heads the Centre for Psychedelic Research and directs the NHS-based CIPPRes Clinic – one of the first clinical services of its kind to integrate psychedelic-assisted approaches into mainstream psychiatric care. His research combines PET, MRI and EEG brain imaging to investigate the neuromechanisms and therapeutic effects of psilocybin, MDMA, DMT and ketamine across conditions including depression, OCD, anorexia nervosa and addiction. Ranked in the top 0.1% of scientists globally in 2025 and the recipient of Imperial's President Award for Excellence in Research, he brings both scientific rigour and clinical depth to one of psychiatry's most rapidly advancing frontiers.
Prof. Dr. med. David Nutt
Professor of Neuropsychopharmacology; Director of the Neuropsychopharmacology Unit (Imperial College London)
He is Edmond J. Safra Professor of Neuropsychopharmacology at Imperial College London, former Chair of the UK's Advisory Committee on the Misuse of Drugs, and in 2024 ranked the world's leading psychopharmacologist by ScholarGPS. With over 500 original research papers and decades at the intersection of brain science, drug policy and clinical practice, he has shaped how governments and clinicians understand psychoactive substances more than perhaps anyone alive. As Chair of DrugScience and a pioneer of psychedelic neuroimaging, he brings both the science and the political reality of psychedelic medicine into sharp focus.
Prof. Dr. med. David Nutt
Professor of Neuropsychopharmacology; Director of the Neuropsychopharmacology Unit (Imperial College London)
He is Edmond J. Safra Professor of Neuropsychopharmacology at Imperial College London, former Chair of the UK's Advisory Committee on the Misuse of Drugs, and in 2024 ranked the world's leading psychopharmacologist by ScholarGPS. With over 500 original research papers and decades at the intersection of brain science, drug policy and clinical practice, he has shaped how governments and clinicians understand psychoactive substances more than perhaps anyone alive. As Chair of DrugScience and a pioneer of psychedelic neuroimaging, he brings both the science and the political reality of psychedelic medicine into sharp focus.
Ethel Rosenfeldt
Psychological Counsellor (Elu Hoiab)
Licensed psychological counsellor who works primarily with adults in both private practice and higher education. She believes that a deeper connection with oneself forms the foundation for a more conscious, fulfilling and meaningful life. In her work, she seeks to expand beyond the traditional one-to-one counselling format by creating opportunities for people to connect more deeply with themselves and with nature. One example is a project that combines sailing with an adventure therapy framework to support young people with ADHD traits. Ethel is currently completing the Open Foundation's two-year ADEPT programme, specialising in psychedelic-assisted therapy, which she sees as a promising approach to fostering deeper self-awareness and lasting personal change. She is a recipient of a TAIP Foundation scholarship and is currently enrolled in the OPEN Foundation's Advanced Education in Psychedelic Therapy (ADEPT) programme.
Ethel Rosenfeldt
Psychological Counsellor (Elu Hoiab)
Licensed psychological counsellor who works primarily with adults in both private practice and higher education. She believes that a deeper connection with oneself forms the foundation for a more conscious, fulfilling and meaningful life. In her work, she seeks to expand beyond the traditional one-to-one counselling format by creating opportunities for people to connect more deeply with themselves and with nature. One example is a project that combines sailing with an adventure therapy framework to support young people with ADHD traits. Ethel is currently completing the Open Foundation's two-year ADEPT programme, specialising in psychedelic-assisted therapy, which she sees as a promising approach to fostering deeper self-awareness and lasting personal change. She is a recipient of a TAIP Foundation scholarship and is currently enrolled in the OPEN Foundation's Advanced Education in Psychedelic Therapy (ADEPT) programme.
Prof. Dr. med. Gerhard Gründer
Professor of Psychiatry; Head of the Department of Molecular Neuroimaging (Central Institute of Mental Health, Mannheim); Medical Director (OVID Clinic Berlin)
Psychiatrist and psychotherapist, Professor at the University of Heidelberg, and Head of Molecular Neuroimaging at the Central Institute of Mental Health in Mannheim, where his research maps the neurobiology of mental disorders and the mechanisms of action of psychotropic substances using PET and fMRI. He led EPIsoDE, Germany's first government-funded psilocybin trial for treatment-resistant depression, and secured the EU's first compassionate use approval for psilocybin in 2025, which is taking place in Mannheim and at the OVID Clinic Berlin, where he is Medical Director. He is arguably Europe's most influential figure in translating psychedelic neuroscience into clinical reality.
Prof. Dr. med. Gerhard Gründer
Professor of Psychiatry; Head of the Department of Molecular Neuroimaging (Central Institute of Mental Health, Mannheim); Medical Director (OVID Clinic Berlin)
Psychiatrist and psychotherapist, Professor at the University of Heidelberg, and Head of Molecular Neuroimaging at the Central Institute of Mental Health in Mannheim, where his research maps the neurobiology of mental disorders and the mechanisms of action of psychotropic substances using PET and fMRI. He led EPIsoDE, Germany's first government-funded psilocybin trial for treatment-resistant depression, and secured the EU's first compassionate use approval for psilocybin in 2025, which is taking place in Mannheim and at the OVID Clinic Berlin, where he is Medical Director. He is arguably Europe's most influential figure in translating psychedelic neuroscience into clinical reality.
Dr Helena Aicher, PhD
Psychotherapist (Psychiatric Clinic, University of Zurich); Postdoctoral Researcher (University of Zurich)
Research associate at the Universities of Zurich and Basel, where she is involved in clinical trials investigating psychedelics. Alongside her research, she works as a psychotherapist with psychedelic-assisted therapy within Switzerland’s framework for limited medical use, primarily in group settings. Bridging scientific research and frontline practice, she contributes to the development and safe implementation of psychedelic-assisted therapies. Helena is also active as a trainer in therapist training programs at the Swiss Medical Association for Psychedelic Therapy (SÄPT) and other organisations, and serves as an advisor to several institutions.
Dr Helena Aicher, PhD
Psychotherapist (Psychiatric Clinic, University of Zurich); Postdoctoral Researcher (University of Zurich)
Research associate at the Universities of Zurich and Basel, where she is involved in clinical trials investigating psychedelics. Alongside her research, she works as a psychotherapist with psychedelic-assisted therapy within Switzerland’s framework for limited medical use, primarily in group settings. Bridging scientific research and frontline practice, she contributes to the development and safe implementation of psychedelic-assisted therapies. Helena is also active as a trainer in therapist training programs at the Swiss Medical Association for Psychedelic Therapy (SÄPT) and other organisations, and serves as an advisor to several institutions.
Kaire Valgeväli
Gestalt Psychotherapist
She holds an MSc in Psychology and is a psychotherapist accredited by the European Association for Psychotherapy (EAP), as well as a Gestalt psychotherapist and Gestalt supervisor accredited by the European Association for Gestalt Therapy (EAGT). Since 2005, she has worked in private practice, providing individual and group psychotherapy as well as supervision. Kaire also serves as President of the Estonian Association for Psychotherapy. Since 2023, her professional interests have expanded to include transpersonal psychology and the practical exploration of altered states of consciousness. She is a recipient of a TAIP Foundation scholarship and is currently enrolled in the OPEN Foundation's Advanced Education in Psychedelic Therapy (ADEPT) programme.
Kaire Valgeväli
Gestalt Psychotherapist
She holds an MSc in Psychology and is a psychotherapist accredited by the European Association for Psychotherapy (EAP), as well as a Gestalt psychotherapist and Gestalt supervisor accredited by the European Association for Gestalt Therapy (EAGT). Since 2005, she has worked in private practice, providing individual and group psychotherapy as well as supervision. Kaire also serves as President of the Estonian Association for Psychotherapy. Since 2023, her professional interests have expanded to include transpersonal psychology and the practical exploration of altered states of consciousness. She is a recipient of a TAIP Foundation scholarship and is currently enrolled in the OPEN Foundation's Advanced Education in Psychedelic Therapy (ADEPT) programme.
Dr Lowan Stewart, MD
Medical Director (Axonklinikken); Medical Research Advisor (PsykForsk, DPS Nordre Østfold)
He is the co-founder of Scandinavia's first public ketamine treatment unit at Sykehuset Østfold (Norway) and continues to advise Norway's public ketamine treatment centres while supporting the implementation of new services across the national healthcare system. As Medical Advisor at PsykForsk (DPS Nordre Østfold), he is involved in clinical trials investigating psilocybin, MDMA, ketamine and esketamine for mood disorders and addiction.
Dr Lowan Stewart, MD
Medical Director (Axonklinikken); Medical Research Advisor (PsykForsk, DPS Nordre Østfold)
He is the co-founder of Scandinavia's first public ketamine treatment unit at Sykehuset Østfold (Norway) and continues to advise Norway's public ketamine treatment centres while supporting the implementation of new services across the national healthcare system. As Medical Advisor at PsykForsk (DPS Nordre Østfold), he is involved in clinical trials investigating psilocybin, MDMA, ketamine and esketamine for mood disorders and addiction.
Prof. Dr. R.A. Robert Schoevers
Professor of Psychiatry; Head of the Department of Psychiatry (University Medical Center Groningen)
Head of the Department of Psychiatry and Director of the Research School of Behavioural and Cognitive Neurosciences at University Medical Center Groningen, where he has specialised in mood and anxiety disorders and treatment-resistant depression since 1990. His research combines clinical psychiatry and epidemiology, with a growing focus on ketamine, psilocybin and MDMA for the most severely ill patients. Since 2015 he has been investigating the potential of psychedelics for patients with severe, hard-to-treat psychiatric illnesses, and he now leads PsyPal, the first EU Horizon-funded clinical trial of psilocybin in non-oncology palliative care, and the Marie Curie Doctoral Network 'Integrate'.
Prof. Dr. R.A. Robert Schoevers
Professor of Psychiatry; Head of the Department of Psychiatry (University Medical Center Groningen)
Head of the Department of Psychiatry and Director of the Research School of Behavioural and Cognitive Neurosciences at University Medical Center Groningen, where he has specialised in mood and anxiety disorders and treatment-resistant depression since 1990. His research combines clinical psychiatry and epidemiology, with a growing focus on ketamine, psilocybin and MDMA for the most severely ill patients. Since 2015 he has been investigating the potential of psychedelics for patients with severe, hard-to-treat psychiatric illnesses, and he now leads PsyPal, the first EU Horizon-funded clinical trial of psilocybin in non-oncology palliative care, and the Marie Curie Doctoral Network 'Integrate'.
Tadeusz Hawrot
Founder and CEO (PAREA)
He has over 15 years of experience working with EU institutions on brain health policy, having led advocacy initiatives for the European Brain Council and the European Federation of Neurological Associations, and contributed to the WHO's global action plan on neurological conditions. As founder and Executive Director of the Psychedelic Access and Research European Alliance (PAREA), he is now focused on driving systemic change in how Europe's healthcare system approaches psychedelic-assisted therapy. His work has been published in journals including The Lancet Neurology, The Lancet Global Health and Nature Reviews Neurology.
Tadeusz Hawrot
Founder and CEO (PAREA)
He has over 15 years of experience working with EU institutions on brain health policy, having led advocacy initiatives for the European Brain Council and the European Federation of Neurological Associations, and contributed to the WHO's global action plan on neurological conditions. As founder and Executive Director of the Psychedelic Access and Research European Alliance (PAREA), he is now focused on driving systemic change in how Europe's healthcare system approaches psychedelic-assisted therapy. His work has been published in journals including The Lancet Neurology, The Lancet Global Health and Nature Reviews Neurology.
Dr Triin Arbo, MD
Child and Adolescent Psychiatrist (Tasapisitasakaal)
Child and adolescent psychiatrist with a strong interest in both biological psychiatry and the influence of relationships and the environment on mental health and human development. Through her clinical work with Eye Movement Desensitization and Reprocessing (EMDR), she has become increasingly aware of the profound impact of life experiences on mental health in children, adolescents and adults. She is interested in treatments that are truly effective, whether pharmacological or psychotherapeutic. Motivated by the challenge of treatment-resistant severe mental disorders, she is open to exploring new therapeutic approaches, including psychedelic-assisted therapy. She is a recipient of a TAIP Foundation scholarship and is currently enrolled in the MIND Foundation's Augmented Psychotherapy Training (APT) programme.
Dr Triin Arbo, MD
Child and Adolescent Psychiatrist (Tasapisitasakaal)
Child and adolescent psychiatrist with a strong interest in both biological psychiatry and the influence of relationships and the environment on mental health and human development. Through her clinical work with Eye Movement Desensitization and Reprocessing (EMDR), she has become increasingly aware of the profound impact of life experiences on mental health in children, adolescents and adults. She is interested in treatments that are truly effective, whether pharmacological or psychotherapeutic. Motivated by the challenge of treatment-resistant severe mental disorders, she is open to exploring new therapeutic approaches, including psychedelic-assisted therapy. She is a recipient of a TAIP Foundation scholarship and is currently enrolled in the MIND Foundation's Augmented Psychotherapy Training (APT) programme.
Viktoria Saat
Psychologist, Coach (Viktoria Saat Consulting)
Psychologist, psychotherapist, and founding member of the Estonian Association for Psychotherapy, where she serves on the Board. Since 2025, she has been participating in the MIND Foundation Berlin's training programme in psychedelic-assisted psychotherapy.
Viktoria Saat
Psychologist, Coach (Viktoria Saat Consulting)
Psychologist, psychotherapist, and founding member of the Estonian Association for Psychotherapy, where she serves on the Board. Since 2025, she has been participating in the MIND Foundation Berlin's training programme in psychedelic-assisted psychotherapy.
Dr Viljar Veede, MD
Psychiatrist (Minu Kliinik); Chairman of the Council (TAIP Foundation)
He previously founded and led Estonia's first ketamine infusion therapy service at Confido Medical Centre and currently provides ketamine-assisted therapy alongside his clinical work in Minu Kliinik. He has completed specialist training in ketamine-assisted psychotherapy (Fluence, USA) and neuropsychopharmacology (ECNP). As Chairman of the Council of the TAIP Foundation, he is actively involved in advancing the safe, ethical and evidence-based implementation of psychedelic-assisted therapies in Estonia.
Dr Viljar Veede, MD
Psychiatrist (Minu Kliinik); Chairman of the Council (TAIP Foundation)
He previously founded and led Estonia's first ketamine infusion therapy service at Confido Medical Centre and currently provides ketamine-assisted therapy alongside his clinical work in Minu Kliinik. He has completed specialist training in ketamine-assisted psychotherapy (Fluence, USA) and neuropsychopharmacology (ECNP). As Chairman of the Council of the TAIP Foundation, he is actively involved in advancing the safe, ethical and evidence-based implementation of psychedelic-assisted therapies in Estonia.
Sihtasutus Teraapia Arenduseks ja Innovatsiooniks Psühhedeelikumidega
info@sataip.ee
Sihtasutus Teraapia Arenduseks ja Innovatsiooniks Psühhedeelikumidega
info@sataip.ee
Sihtasutus Teraapia Arenduseks ja Innovatsiooniks Psühhedeelikumidega
info@sataip.ee